Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 8, 2010 - Issue 9
Submit an article Journal homepage
186
Views
9
CrossRef citations to date
0
Altmetric
Review

Stents and statins: history, clinical outcomes and mechanisms

Pradeep K Nair Center for Interventional Cardiology Research, Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, A-333 PUH, Pittsburgh, PA 15213, USA; Center for Interventional Cardiology Research, Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, A-333 PUH, Pittsburgh, PA 15213, USA
,
Suresh R Mulukutla Center for Interventional Cardiology Research, Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, A-333 PUH, Pittsburgh, PA 15213, USA; Center for Interventional Cardiology Research, Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, A-333 PUH, Pittsburgh, PA 15213, USA
&
Oscar C Marroquin Center for Interventional Cardiology Research, Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, A-333 PUH, Pittsburgh, PA 15213, USA;[email protected]
Pages 1283-1295 | Published online: 10 Jan 2014

References

  • Dawber TR, Kannel WB, Revotskie N et al. Some factors associated with the development of coronary heart disease. Six years’ follow-up experience in the Framingham Study. Am. J. Public Health Nations Health49, 1349–1356 (1959).
  • Kirby TJ. Cataracts produced by triparanol. Trans. Am. Ophthalmol. Soc.65, 494–543 (1967).
  • Tobert JA. Lovastatin and beyond: the history of the HMG-COA reductase inhibitors. Nat. Rev. Drug Discov.2, 517–526 (2003).
  • Lowering blood cholesterol to prevent heart disease. NIH Consens. Statement5, 1–11 (1984).
  • Endo A, Tsujita Y, Kuroda M et al. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot.29, 1346–1348 (1976).
  • Endo A, Tsujita Y, Kuroda M et al. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3methylglutaryl-coenzyme A reductase. Eur. J. Biochem.77, 31–36 (1977).
  • Alberts AW, Chen J, Kuron G et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl Acad. Sci. USA77, 3957–3961 (1980).
  • Bilheimer DW, Grundy SM, Brown MS et al. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl Acad. Sci. USA80, 4124–4128 (1983).
  • Illingworth DR, Sexton GJ. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J. Clin. Invest.74, 1972–1978 (1984).
  • Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA256, 2829–2834 (1986).
  • Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA260, 359–366 (1988).
  • Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for the treatment of severe primary hypercholesterolemia. Am. J. Cardiol.66, 22B–30B (1990).
  • Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet344, 1383–1389 (1994).
  • Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med.335, 1001–1009 (1996).
  • Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.339, 1349–1357 (1998).
  • Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation30, 654–670 (1964).
  • Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med.301, 61–68 (1979).
  • Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med.316, 701–706 (1987).
  • Schatz RA, Palmaz JC, Tio FO et al. Balloon-expandable intracoronary stents in the adult dog. Circulation76, 450–457 (1987).
  • Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med.331, 489–495 (1994).
  • Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med.331, 496–501 (1994).
  • Holmes DR Jr, Savage M, LaBlanche JM et al. Results of Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation106, 1243–1250 (2002).
  • Holmes DR Jr, Teirstein P, Satler L et al. Sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis within bare-metal stents. JAMA295, 1264–1273 (2006).
  • Stone GW, Ellis SG, O’Shaughnessy CD et al. Paclitaxel-eluting stents versus vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA295, 1253–1263 (2006).
  • Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349, 1315–1323 (2003).
  • Grines CL. Off-label use of drug-eluting stents putting it in perspective. J. Am. Coll. Cardiol.51, 615–617 (2008).
  • Serruys PWJ, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA287, 3215–3222 (2002).
  • Chan AW, Bhatt DL, Chew DP et al. Early and sustained therapy at the time of percutaneous coronary intervention. Circulation105, 691–696 (2002).
  • Schomig A, Mehilli J, Holle H et al. Statin treatment following coronary artery stenting and one-year survival. J. Am. Coll. Cardiol. 40, 854–861 (2002).
  • Kasai T, Miyauchi K, Kurata T et al. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int. J. Cardiol. 114, 210–217 (2007).
  • Zhang ZJ, Marroquin OC, Weissfeld JL et al. Beneficial effects of statins after percutaneous coronary intervention. Eur. J. Cardiovasc. Prev. Rehabil.16, 445–450 (2009).
  • Johnson C, Waters DD, DeMicco DA et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] study). Am. J. Cardiol.102, 1312–1317 (2008).
  • Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med.356, 1503–1516 (2007).
  • Smith SC, Feldman TE, Hirshfeld JW et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.47, e1–e121 (2006).
  • Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA285, 1711–1718 (2001).
  • Gibson CM, Pride YB, Hochberg CP et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22) Substudy. J. Am. Coll. Cardiol.54, 2290–2295 (2009).
  • Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous intervention. J. Am. Coll. Cardiol.49, 1272–1278 (2007).
  • Yun KH, Jeong MH, Oh SK et al. The beneficial effects of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int. J. Cardiol.137, 246–251 (2009).
  • Kim JS, Kim J, Choi D et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarctiom. J. Am. Coll. Cardiol. Intv.3, 332–339 (2010).
  • Bertrand ME, McFadden EP, Fruchart JC et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J. Am. Coll. Cardiol.30, 863–869 (1997).
  • Mulder HJ, Bal ET, Jukema JW et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am. J. Cardiol.86, 742–746 (2000).
  • Weintraub WS, Boccuzzi SJ, Klein JL et al. Lack of effect of lovastatin on restenoses after coronary angioplasty. N. Engl. J. Med.331, 1331–1337 (1994).
  • Serruys PW, Foley DP, Jackson G et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty. Eur. Heart J.20, 58–69 (1999).
  • Zhang ZJ, Cheng Q, Jiang GX et al. Statins in prevention of repeat revascularization after percutaneous coronary intervention – a meta-analysis of randomized clinical trials. Pharmacol. Res.61, 316–320 (2010).
  • Walter DH, Schachinger V, Elsner M et al. Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol.85, 962–968 (2000).
  • Bunch TJ, Muhlestein JB, Anderson JL et al. Effects of stain on six-month survival and clinical restenosis frequency after coronary stent deployment. Am. J. Cardiol.90, 299–302 (2002).
  • Bae JH, Bassenge E, Kim KY et al. Effects of low dose atorvastatin on vascular response in patients undergoing percutaneous coronary intervention with stenting. J. Cardiovasc. Pharmacol. Ther.9, 185–192 (2004).
  • Hong YH, Jeong MH, Hyun DW et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am. J. Cardiol.95, 619–622 (2005).
  • Kamishirado H, Inoue T, Sakuma M et al. Effects of statins on restenosis after coronary stent implantation. Angiology58, 55–60 (2007).
  • Brener SJ, Ellis SG, Schneider J et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur. Heart J.24, 225–248 (2002).
  • Ioannidis JPA, Karvouni E, Kastrisis DG. Mortality risk conferred by small elevation of creatinine kinase-MB isoenzyme after percutaneous coronary intervention. J. Am. Coll. Cardiol.42, 1406–1411 (2003).
  • Cavallini C, Savonitto S, Violini R et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary interventions: results of the CK-MB and PCI study. Eur. Heart J.26, 1494–1498 (2005).
  • Roe MT, Mahaffey KW, Kilaru R et al. Creatinine kinase-MB elevation after percutaneous coronarty intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur. Heart J.25, 313–321 (2004).
  • Turer AT, Mahaffey KW, Gallup D et al. Enzyme estimates of infarct size correlates with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr. Control. Trials Cardiovasc. Med.6, 12–15 (2005).
  • Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction. Circulation116, 2634–2653 (2007).
  • Mulukutla SR, Marroquin OC, Smith C et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am. J. Cardiol.94, 1363–1366 (2004).
  • Briguori C, Colombo A, Airoldi F et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur. Heart J.25, 1822–1828 (2004).
  • Herrmann J, Lerman A, Baumgart D et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation106, 2180–2183 (2002).
  • Pasceri V, Patti G, Nusca A et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention. Circulation110, 674–678 (2004).
  • Merla R, Reddy N, Wang FW et al. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am. J. Cardiol.100, 770–776 (2007).
  • Briguori C, Visconti G, Focaccio A et al. Novel Approaches for Preventing or Limiting Events (Naples) II trial. J. Am. Coll. Cardiol.54, 2157–2163 (2009).
  • Cay S, Cagirci G, Sen N et al. Prevention of periprocedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc. Drugs Ther.24, 41–47 (2010).
  • Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J. Am. Coll. Cardiol.54, 558–565 (2009).
  • Erbel R, Heusch G. Brief review: coronary microembolization. J. Am. Coll. Cardiol.36, 22–24 (2000).
  • Heusch G, Kleinbongard P, Bose D et al. Coronary microembolization. From bedside to bench and back to bedside. Circulation120, 1822–1836 (2009).
  • Dorge H, Neumann T, Behrends M et al. Perfusion–contraction mismatch with coronary microvascular obstruction: role of inflammation. Am. J. Physiol. Heart Circ. Physiol.279, H2587–H2592 (2000).
  • Dorge H, Schulz R, Belosjorow S et al. Coronary microembolization: the role of TNF-α in contractile dysfunction. J. Mol. Cell. Cardiol. 34, 51–62 (2002).
  • Thielmann M, Dorge H, Martin C et al. Myocardial dysfunction with coronary microembolization. Signal transduction through a sequence of nitric oxide, tumor necrosis factor-α, and sphingosine. Circ. Res.90, 807–813 (2002).
  • Skyschally A, Haude M, Dorge H et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation109, 2337–2342 (2004).
  • Gaspardone A, Versaci F. Coronary stenting and inflammation. Am. J. Cardiol.96(Suppl.), 65L–70L (2005).
  • Gawaz M, Neumann FJ, Ott I et al. Platelet activation and coronary stent implantation: effect of antithrombotic therapy. Circulation94, 279–285 (1996).
  • Welt FG, Tso C, Edelman ER et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc. Med.8, 1–7 (2003).
  • Grewe PH, Deneke T, Machraoui A et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimens. J. Am. Coll. Cardiol.35, 157–163 (2000).
  • Jabs WJ, Theissing E, Nitschke M et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation108, 1428–1431 (2003).
  • Yasojima K, Schwab C, McGeer EG et al. Generation of C-reactive protein and complement components in atherosclerotic plaque. Am. J. Pathol.158, 1039–1051 (2001).
  • Zwaka TP, Hombach V, Torzewski J et al. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atheroscleoris. Circulation103, 1194–1197 (2001).
  • Fitchlscherer S, Rosenberger G, Walter DH et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation102, 1000–1006 (2000).
  • Fukuda D, Shimada K, Tanaka A et al. Circulating monocytes and in-stent neointima after coronary stent implantation. J. Am. Coll. Cardiol.43, 18–23 (2004).
  • Gaspardone A, Crea F, Versaci F et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am. J. Cardiol.82, 515–518 (1998).
  • Dibra A, Mehilli J, Braum S et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am. Heart J.150, 344–350 (2005).
  • Walter DH, Fichtlscherer S, Sellwig M et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J. Am. Coll. Cardiol. 37, 839–846 (2001).
  • Jialal I, Stein D, Balis D et al. Effect of hydroxymethyl-glutaryl-coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation103, 1933–1935 (2001).
  • Rezaie-Majd A, Prager GW, Bucek RA et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol.23, 397–403 (2003).
  • Patti G, Pasceri V, Colonna G et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J. Am. Coll. Cardiol.48, 1560–1566 (2006).
  • Bellosta S, Via D, Canavesi M et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol.18, 1671–1678 (1998).
  • Sanguigni V, Pignatelli P, Lenti L et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation111, 412–419 (2005).
  • Chan KC, Wang CJ, Ho HH et al. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol. Res.58, 247–256 (2008).
  • Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Artierioscler. Thromb. Vasc. Biol.21, 1712–1719 (2001).
  • Morikawa S, Takabe W, Mataki C et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J. Atheroscler. Thromb.9, 178–183 (2002).
  • Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation62, 193–197 (2004).
  • Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA279, 1643–1650 (1998).
  • Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am. J. Cardiol.91, 4B–8B (2003).
  • Laufs U, La Fata V, Plutzky J et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation97, 1129–1135 (1998).
  • Jain MK, Ridker PM. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov.4, 977–987 (2005).
  • Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol.96, 24F–33F (2005).
  • Laufs U, Endres M, Custodis F et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation102, 3104–3110 (2000).
  • Heeschen C, Hamm CW, Laufs U et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation2002, 1446–1452 (2002).
  • Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation98, 839–844 (1998).
  • Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med.352, 20–28 (2005).
  • Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
  • Gaspardone A, Versaci F, Proietti I et al. Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation C-reactive protein and six-month clinical events. Am. J. Cardiol.90, 31–33 (2002).
  • Chan AW, Bhatt DL, Chew DP et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation107, 1750–1756 (2003).
  • Walter DH, Fichtlscherer S, Britten MB et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J. Am. Coll. Cardiol.38, 2006–2012 (2001).
  • Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am. J. Cardiol.91, 4B–8B (2003).
  • Sukhova GK, Schonbeck U, Rabkin E et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable atheromatous plaques. Circulation99, 2503–2509 (1999).
  • Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet367, 69–78 (2006).
  • Yonemura A, Momiyama Y, Fayad ZA et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic plaques: a 2-year follow-up by noninvasive MRI. Eur. J. Cardiovasc. Prev. Rehabil.16, 222–228 (2009).
  • Schartl M, Bocksch W, Koschyk DH et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation104, 387–392 (2001).
  • Okazaki S, Yokoyama T, Miyauchi K et al. Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation110, 1061–1068 (2004).
  • Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA291, 1071–1080 (2004).
  • Crouse JR III, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA297, 1344–1353 (2007).
  • Nair A, Kuban BD, Tuzcu EM et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation106, 2200–2206 (2002).
  • Philipp S, Bose D, Wijns W et al. Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry. Eur. Heart J.31, 196–202 (2010).
  • Virmani R, Burke AP, Farb A et al. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol.47, C13–C18 (2006).
  • Kawamoto T, Okura H, Koyama Y et al. The relationship between coronary plaque characteristics and small embolic particles during coronary stent implantation. J. Am. Coll. Cardiol.50, 1635–1640 (2007).
  • Boese D, von Birgelen C, Zhou XY et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. Basic Res. Cardiol.103, 587–597 (2008).
  • Nasu K, Tsuchikane E, Katoh O et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology. JACC Cardiovasc. Interv.7, 689–696 (2009).
  • Hong MK, Park DW, Lee CW et al. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc. Interv.7, 679–688 (2009).
  • Toi T, Taguchi I, Yoneda S et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ. J.73, 1466–1472 (2009).
  • Takano M, Mizuno K, Yokoyama S et al. Changes in coronary plaque color and morphology by lipid lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J. Am. Coll. Cardiol.42, 680–686 (2003).
  • Hirayama A, Saito S, Ueda Y et al. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ. J.73, 718–725 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.